

Journal name: Applied Microbiology and Biotechnology

DnaJ, a promising vaccine candidate against *Ureaplasma urealyticum* infection

Authors: Fangyi Guo ^{1,2,3}, Yanhong Tang ⁴, Wenjun Zhang ^{1,3}, Hongxia Yuan ³, Jing Xiang ³, Wenyong Teng ³, Aihua Lei ², Ranhui Li ^{2*} and Guozhi Dai ^{1,3*}

Institution:¹ The Chenzhou Affiliated Hospital, Hengyang Medical School, University of South China, Chenzhou, China

² Pathogenic biology Institute, Hengyang Medical School, University of South China, Hengyang, China

³ The First People's Hospital of Chenzhou, Chenzhou, China

⁴ State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou, China

*Corresponding author: Guozhi Dai

The Chenzhou Affiliated Hospital, Hengyang Medical School, University of South China

Chenzhou, 423000, China

Tel: 86 13975522423

Fax: 86 0735-2345651

E-mail: daigz008@126.com

Ranhui Li

Pathogenic biology Institute, Hengyang Medical School, University of South China

Hengyang, 421000, China

Tel: 86 18073467183

Fax: 86 0734 8292761

E-mail: Ranhui81@163.com

Figure S1




Figure S1 The specific marker of BMDCs. Generation of BMDCs from the bone marrow precursors after 6 d culture with 10 ng/mL GM-CSF and 10 ng/mL IL-4. (A) CD11c⁺ cells were detected by FACS. More than 90% of the suspension cells expressed CD11c. (B) Purity of BMDCs cultures as determined by FACS using expression of BMDC markers CD11c and CD11b.

Table S1. Evaluation of the conservative distribution of *Ureaplasma urealyticum* (Uu)-DnaJ protein sequences.

Order	Serovars	Identities(%)	Positives(%)	Gaps(%)	E
1	Serovar 2	100%	100%	0	0
2	Serovar 4	100%	100%	0	0
3	Serovar 5	100%	100%	0	0
4	Serovar 7	100%	100%	0	0
5	Serovar 8	100%	100%	0	0
6	Serovar 9	99%	99%	0	0
7	Serovar12	100%	100%	0	0
8	Serovar 13	100%	100%	0	0

Table S2. Uu-DnaJ CTL predicted epitopes

S. No.	Peptide	Peptide	Length	Peptide	HLA class I allele restriction
1	262	270	9	FAFDGLDIY	HLA-A*01:01; HLA-B*35:01
2	357	365	9	RTNQSVEYY	HLA-A*01:01
3	280	288	9	AIVGGVIEV	HLA-A*02:01; HLA-A*02:06
4	196	204	9	GTGKVANSK	HLA-A*11:01
5	22	30	9	KTAFRKLAK	HLA-A*03:01; HLA-A*11:01
6	111	119	9	SSSSQYETY	HLA-A*01:01; HLA-B*35:01
7	17	25	9	SPEEIKTAF	HLA-B*07:02; HLA-B*08:01 HLA-B*35:01
8	273	281	9	TYVDPIKAI	HLA-A*24:02; HLA-A*23:01 HLA-A*24:02; HLA-A*02:06

Table S3. Uu-DnaJ HTL predicted epitopes

S. No.	Peptide start	Peptide	Length	Peptide
1	346	360	15	EEIAYLKNISARTNQ
2	99	113	15	FGSFFKNGASSRSSH
3	257	271	15	KPSKYFAFDGLDIYS
4	305	319	15	EGKKFRISGAGIVNK
5	62	76	15	AQYDQFGHDGPQGFA
6	19	33	15	EEIKTAFRKLAKHH
7	127	141	15	LEFIEAIKGVSKNIS

Figure S2




Figure S2 Representative photographs of the vulva in mice 14 days after infection.

Figure S3




Figure 3 The noncytotoxic dose of DnaJ on BMDCs was detected. BMDCs were treated with DnaJ at a concentration from 2.5 µg/mL to 80 µg/mL with for 48 h, and the LDH activity in the supernatant was measured with a kit, ns = not significant, $P > 0.05$.